EGFR and neoplasm: Empirical results have gone on to confirm the high binding specificity and selectivity of the anti-EGFR nanobody, with a demonstrated difference in uptake between tumor cells overexpressing EGFR (A431 cells) and those with a slightly more moderate expression (DU145 cells) [47,48].